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DESCRIPTION
DRUG DELIVERY INTEGRATED CIRCUIT (IC) AND SYSTEM
CROSS REFERENCE TO RELATED APPLICATION
This application claims the benefit of U.S. Provisional Application Serial No.
62/297,383, filed February 19, 2016, the disclosure of which is hereby incorporated by
reference in its entirety, including any figures, tables, and drawings.
BACKGROUND OF INVENTION
Drug delivery refers to approaches, formulations, technologies, and systems for
transporting a pharmaceutical compound in the body to safely achieve its desired
therapeutic effect. It often involves scientific site-targeting within the body or facilitating
systemic pharmacokinetics. In any case, it is typically concerned with both the quantity and
duration of drug presence. Drug delivery is often approached via a drug's chemical
formulation, but it may also involve medical devices or drug-device combination products.
Drug delivery is a concept heavily integrated with dosage form and route of administration,
the latter sometimes even being considered part of the definition.
Devices capable of the precise control of levels of drugs in specific tissues or the
blood stream can enable maintenance of the drug within a therapeutic window (effective yet
not associated with undesirable side effects). Many conditions, including Alzheimer's
disease, cancer, cardiovascular diseases, diabetes, epilepsy, pain, Parkinson's disease, and
infectious diseases can be treated most effectively by drugs with chronopharmacologies
synchronized with the chronobiology of the specific condition.
Current efforts in the area of drug delivery include targeted delivery in which the
drug is only active in the target area of the body (for example, in cancerous tissues) and
sustained release formulations in which the drug is released over a period of time in a
controlled manner from a formulation. Types of sustained release formulations include
liposomes, drug-loaded biodegradable microspheres and drug-polymer conjugates.
However, drawbacks of the related art include the need to be tethered to stationary
equipment and constant human intervention to control the quantity, duration, and target site
of drus delivery.
BRIEF SUMMARY
To address the above-mentioned problems, new equipment and methods are needed
for drug delivery. The subject invention provides novel and advantageous drug delivery
systems and methods.
In one embodiment, a drug delivery system includes a control module, a wireless drug
delivery integrated circuit (WDDIC), a first electrode and a second electrode that are both
attached to the wireless drug delivery integrated circuit, a first electroactive polymer, and a
first pharmaceutical compound.
In another embodiment, a drug delivery method includes providing a wireless drug
delivery integrated circuit, providing a control module suitable for controlling the wireless
drug delivery integrated circuit, providing a first electrode and a second electrode that are
both attached to the wireless drug delivery integrated circuit, providing a first electroactive
polymer, providing a first pharmaceutical compound, and releasing the first pharmaceutical
compound into a first solution by generating a first voltage difference between the first
electrode and the second electrode.
In another embodiment, a drug delivery integrated circuit (DDIC) includes a first
electrode and a second electrode that are both attached to the DDIC, a first electroactive
polymer, and a first pharmaceutical compound. The DDIC is suitable for releasing the first
pharmaceutical compound into a first solution by generating a first voltage difference
between the first electrode and the second electrode, and the DDIC can be pre-programmed
to begin drug release upon crossing a measurement threshold. The measurement threshold
can include one or more of a temperature, sugar level, time, and a concentration. Other
factors along these lines can be included in the measurement threshold.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 is a block diagram of a wireless drug delivery integrated circuit (IC)
system according to an embodiment of the present invention.
Figure 2 is a block diagram of a wireless drug delivery integrated circuit (IC)
according to an embodiment of the present invention.
Figure 3 is a block diagram of an embodiment of the present invention that has
multiple gel/solution modules with separate micropumps.
Figure 4 is a block diagram of an embodiment of the present invention that has
multiple gel/solution modules using one micropump and a flow controller.
Figure 5 is a simplified block diagram of an embodiment of the present invention.
Figure 6 illustrates the structure of electroactive polymers including oligoanilines
linked to polycaprolactone (PCL, 2kDa) via ester bonds.
Figure 7 shows an experimental test setup of a wireless drug delivery integrated
circuit attached to an electrochemical cell with a U.S. quarter dollar coin for comparison.
Figure 8 is an image of an embodiment of a wireless drug delivery integrated circuit
according to an embodiment of the present invention.
Figure 9 is circuit diagram of the bias controller, power supply, and a part of the
MCU of the embodiment shown in Figure 8 .
Figure 10 is an image of the user interface of an embodiment of the control module
of the present invention.
Figure 11 is an image of an embodiment of a drug delivery integrated circuit of the
present invention.
Figure 12 is a graph illustrating the percentage of dexamethasone phosphate (DMP)
released from films of biodegradable electroactive polymers over time, with and without
electrical stimulation.
DETAILED DISCLOSURE
The subject invention provides novel and advantageous drug delivery methods,
systems, and methods of using the systems. More specifically, the subject invention
provides a drug delivery integrated circuit, system, and method of wirelessly delivering
therapeutic pharmaceutical compounds.
A drug delivery system can include a control module, a wireless drug delivery
integrated circuit (WDDIC), a first electrode and a second electrode that are both attached to
the wireless drug delivery integrated circuit, a first electroactive polymer, and a first
pharmaceutical compound. The first electroactive polymer and the first pharmaceutical
compound can be layered in films on the first electrode. The drug delivery system can have
multiple antennas that are suitable for supplying energy to the wireless drug delivery
integrated circuit. The first electrode can be made of, for example, bioinert glassy carbon,
and the second electrode can be made of, for example, platinum. Other non-limiting
examples of electrode materials include steel, platinum, iridium oxide, gold, magnesium,
tungsten, silicon, and platinum-iridium. The drug delivery system can further include a third
electrode and a fourth electrode in a second chamber with a second pharmaceutical
compound, wherein the first electrode and the second electrode are contained in a first
chamber with the first pharmaceutical compound. The drug delivery system can also
include an inlet, an outlet, and a micropump as a secondary method of drug delivery control.
A drug delivery method can include providing a WDDIC, providing a control
module suitable for controlling the WDDIC, providing a first electrode and a second
electrode, which are both attached to the WDDIC, providing a first electroactive polymer,
providing a first pharmaceutical compound, and releasing the first pharmaceutical
compound into a first solution by generating a first voltage difference between the first
electrode and the second electrode. The drug delivery method can further include providing
a third electrode and a fourth electrode and releasing a second pharmaceutical compound.
The method can further include providing a first chamber that contains the first solution, the
first electrode, and the second electrode and providing a first inlet, a first micropump, and a
first outlet, wherein the release of the first pharmaceutical compound out of the first
chamber uses the first inlet, the first micropump, and the first outlet. The first polymer can
include, for example, oligoanilines linked to polycaprolactone (PCL, 2kDa) via ester bonds,
though embodiments are not limited thereto and other electroactive polymers can be used.
The first electroactive polymer and the first pharmaceutical compound can be layered in
films on the first electrode.
A non-wirelessly controlled embodiment of the present invention includes providing
a drug delivery integrated circuit (DDIC), providing a first electrode and a second electrode
that are both attached to the DDIC, providing a first electroactive polymer, providing a first
pharmaceutical compound, and releasing the first pharmaceutical compound into a first
solution by generating a first voltage difference between the first electrode and the second
electrode. The DDIC can be pre-programmed to begin control of drug release upon
crossing a measurement threshold, and the measurement threshold can include one or more
of a temperature, sugar level, time, concentration, and so forth. The DDIC can also include
one or more of the additional features discussed with regards to the WDDIC, such as more
than two electrodes, more than one drug, more than one polymer, one or more chambers,
one or more inlets/outlets, and/or a flow controller.
Drug delivery systems can use polymer-based materials to improve pharmacological
and therapeutic properties. Polymers have been used as elements in drug delivery
technology because they can control the release of therapeutic agents. Although there are
many clinical implementation hurdles, intelligent drug delivery systems can bring
innovation and change to the treatment of diseases. Stimuli-responsive drug delivery
systems are particularly useful in the treatment of such conditions because they have
potential for spatiotemporally controlled drug delivery. Materials responding to stimuli
such as enzymes, light, pH, temperature, ultrasound, and electric/magnetic fields can be
used as drug delivery devices. Biodegradable electroactive/conductive polymer-based
materials for electrochemically triggering drug delivery can also be used. Examples of
polymers that can be applied in the present invention include poly(fluorene)s,
polyphenylenes, polypyrenes, polyazulenes, polynaphthalenes, poly(acetylene)s, poly(p-
phenylene vinylene), poly(pyrrole)s, polycarbazoles, polyindoles, polyazepines,
polyanilines, poly(thiophene)s, poly(3,4-ethylenedioxythiophene), and poly(p-phenylene
sulfide).
The miniaturization and integration of wireless and non-wireless drug delivery
systems is an essential step for practical use of drug delivery applications. In embodiments
of the present invention, wireless drug delivery integrated circuits, systems, and methods of
wirelessly delivering therapeutic pharmaceutical compounds are presented. In addition,
non-wireless drug delivery integrated circuits, systems, and methods of delivering
therapeutic pharmaceutical compounds are presented. Applications for this invention
include, for example, implantable (e.g, in the bloodstream or at a site where delivery is
desired) and non-implantable use (e.g.,, via an intravenous therapy bag) in humans and
other animals.
Figure 1 is a simplified block diagram of a wireless drug delivery integrated circuit
(IC) and system according to an embodiment of the present invention. Referring to Figure
1, the system includes a laptop acting as the control module and the wireless drug delivery
integrated circuit (WDDIC). The WDDIC has various components including a power
management unit, a temperature sensor, a CPU, radio frequency (RF) transceivers, an RF-
to-DC energy conversion circuit, on-chip antennas, an electrochemical cell and its
controller, a micropump and its controller, a battery/supercapacitor, read-only memory
(ROM), random access memory (RAM), an analog to digital converter (ADC), a digital to
analog converter (DAC), a timer, an oscillator, and I/O ports. Further, all of the
components except for the electrochemical cell, micropump, and battery/supercapacitor can
be integrated in a single circuit board.
The antennas can act solely as signal transmitters or can also be a source of power.
The on-chip antennas can be stacked on the IC, or they can be fabricated using one of the
R layers of the IC. It is preferable that antennas be integrated in the chip and work at high
frequency bands to miniaturize the system. If the antennas work at low frequency bands,
they may be too large to integrate on the chip. If it is desired for the antennas to operate at a
low frequency band, they can be implemented as off-chip components that are attached to
or stacked on the IC. Ranges of frequency bands that could be applied in the present
invention include 1 kHz - 1 MHz, 10 kHz - 1 GHz, 10 MHz-1 GHz, and 1 GHz- 10 THz,
and 3Hz to 300 GHz. It should also be understood that different ranges of frequencies may
be used for harvesting than for communication and more than one frequency band may be
used for communication, energy harvesting, or both. One antenna may be used; however,
multiple antennas can be used to increase energy harvesting efficiency. The RF-to-DC
conversion varies by frequency, and the use of multiple frequency bands and multiple
antennas can provide a better chance of good RF-to-DC conversion as there are many RF
frequency standards that use various frequencies.
Even if only one RF frequency band is used for both the energy conversion and
communication, multiple antennas can still help increase energy efficiency. If multiple
antennas are used, a phased array antenna can be formed to increase performance. For
instance, if there are three ambient frequency bands and three antennas (or antenna groups
such as in phased array antennas), the RF-to-DC conversion can operate using all three
frequencies, thereby increasing the likelihood of efficient RF-to-DC conversion. Modern
wireless power transfer generally operates in low frequency bands, which require relatively
large antennas. However, if the frequency bands are chosen properly, the use of multiple
antennas using one or more frequency bands can be fabricated in a portable or even
implantable size. As the drug delivery IC can have multiple antennas and transceivers, it
can support multiple RF standards including Bluetooth, Bluetooth low energy, NFC, ANT
and ANT+, Zigbee, WiFi, Cellular network including 2G, 3G, 4G, 5G, and satellite
communication, as well as others.
A battery (one time use or rechargeable) or supercapacitor may be used to power the
portable device. That is, if RF power is sufficient, a battery may not be necessary. Because
it is not currently feasible to fully integrate the battery/supercapacitor on a chip, they can be
fabricated separately and attached or stacked on the IC.
Figure 2 illustrates a wireless drug delivery system according to an embodiment of
the present invention. Referring to Figure 2, the system includes digital and RF circuits, on-
chip antennas, a micropump, an inlet, an outlet, an electrochemical cell, a micropump driver
and electrochemical cell controller, electrodes, a solution/gel, a waterproof case/package,
and a battery/supercapacitor. As discussed herein, it is preferable to implement all the
components on a single chip, but they can alternatively be stacked or attached to the circuit
board. The electronics, wafer, and/or IC package can be surrounded by a waterproof case to
protect it from the surrounding environment.
As shown in Figures 2, 3, and 4, the electrochemical cell can have more electrodes
than just a single anode and cathode. More than two electrodes can be used for failure
redundancy and/or controlling the release of one drug using multiple potentials, or different
electrodes can be coated with different drugs for individual controlled release. In addition,
as illustrated in Figures 3 and 4, multiple different drugs or the same drug can be stored in
different solution/gel compartments (or chambers), and their release can be controlled by
different electrodes. For example, one, two, three, four, five, six or even more pairs of
electrodes can release one, two, three, four, five, six or even more types of drugs. In
another example, one, two, three, four, five, six or even more anodes can be used with one
cathode (or vice versa, i.e., one, two, three, four, five, six or even more cathodes can be
used with one anode). In addition, one, two, three, four or even more drugs can be
combined on a single electrode. Examples of drugs that can be applied to the present
invention include anions (e.g. ATP, dexamethasone, glutamate, salicylate, naproxen),
cations (e.g. dopamine and chlorpromazine), and neutral compounds (e.g., nerve growth
factor). If desired, micropumps can be added for further controlling drug release.
Alternatively, instead of using electrodes, one, two, three, four, five, six or even more types
of drugs can be administered solely using compartments containing drug solutions and be
administered via one, two, three, four, five, six or even more micropumps. And, instead of
using multiple micropumps, one micropump with a flow controller can be used for
controlling the release of different drugs, as shown in Figure 4 . A mixing unit may also be
provided in which drugs are mixed before being administered.
The electrodes can maintain a constant potential difference (e.g., 0.6 V for a period
of time, such as 30 seconds, and then turn off), the potentials can change over time (e.g.,
increase from 0.2V - 0.6V over a period of time, such as 30 seconds), or multiple different
potentials can be enabled for different time periods (i.e., the voltage difference and time
durations can be arbitrarily selected and are only limited by the hardware components). In
further embodiments, the potential difference across the electrodes can be sinusoidal, saw
tooth, rectangular/square, and triangular waves as well as pulse width modulation. The
wireless controller device can also monitor and send temperature data, humidity, blood
analysis, sugar levels, and so forth. In biological applications, temperature data is an
important factor to be considered as the temperature of a patient is indicative of their health
and can influence the rate of drug release from a polymer-based drug delivery device.
Figure 5 illustrates a wireless drug delivery integrated system according to an
embodiment of the present invention that includes an electroactive polymer cell, a control
module (laptop and wireless module), and wireless drug delivery integrated circuit (i.e., a
WDDIC). An electrochemical cell is connected to the WDDIC. The WDDIC includes a
bias controller, a boost converter, a coin cell battery, a temperature sensor, a lower-power
MCU, LEDs, a button, an I C connector, and a wireless module (e.g., a 2.4 GHz wireless
module).
The methods and processes described herein can be embodied as code and/or data.
The software code and data described herein can be stored on one or more computer-
readable media, which may include any device or medium that can store code and/or data
for use by a computer system. When a computer system reads and executes the code and/or
data stored on a computer-readable medium, the computer system performs the methods
and processes embodied as data structures and code stored within the computer-readable
storage medium.
It should be appreciated by those skilled in the art that computer-readable media
include removable and non-removable structures/devices that can be used for storage of
information, such as computer-readable instructions, data structures, program modules, and
other data used by a computing system/environment. A computer-readable medium
includes, but is not limited to, volatile memory such as random access memories (RAM,
DRAM, SRAM); and non-volatile memory such as flash memory, various read-only-
memories (ROM, PROM, EPROM, EEPROM), magnetic and ferromagnetic/ferroelectric
memories (MRAM, FeRAM), and magnetic and optical storage devices (hard drives,
magnetic tape, CDs, DVDs); network devices; or other media now known or later
developed that is capable of storing computer-readable information/data. Computer-
readable media should not be construed or interpreted to include any propagating signals. A
computer-readable medium of the subject invention can be, for example, a compact disc
(CD), digital video disc (DVD), flash memory device, volatile memory, or a hard disk drive
(HDD), such as an external HDD or the HDD of a computing device, though embodiments
are not limited thereto. A computing device can be, for example, a laptop computer,
desktop computer, server, cell phone, or tablet, though embodiments are not limited thereto.
The subject invention includes, but is not limited to, the following exemplified
embodiments.
Embodiment 1 . A drug delivery system comprising:
a control module;
a wireless drug delivery integrated circuit;
a first electrode and a second electrode, which are both attached to the wireless drug
delivery integrated circuit;
a first electroactive polymer; and
a first pharmaceutical compound.
Embodiment 2 . The drug delivery system of embodiment 1, wherein the first
electroactive polymer and the first pharmaceutical compound are layered as films on the
first electrode.
Embodiment 3 . The drug delivery system of any of embodiments 1-2, wherein the
wireless drug delivery integrated circuit includes multiple antennas that are suitable for
supplying energy to the wireless drug delivery integrated circuit.
Embodiment 4 . The drug delivery system of any of embodiments 1-3, wherein the
first electrode is comprised of a bioinert glassy carbon.
Embodiment 5 . The drug delivery system of any of embodiments 1-4, wherein the
second electrode is comprised of platinum.
Embodiment 6 . The drug delivery system of any of embodiments 1-5, further
comprising a third electrode and a fourth electrode in a second chamber with a second
pharmaceutical compound, and wherein the first electrode and the second electrode are
contained in a first chamber with the first pharmaceutical compound.
Embodiment 7 . The drug delivery system of any of embodiments 1-6, further
comprising an inlet, an outlet, a chamber, and a micropump.
Embodiment 8 . The drug delivery system of any of embodiments 1-7, further
comprising:
a first inlet, a first outlet, and a first micropump in the first chamber; and a second
inlet, a second outlet, and a second micropump in the second chamber.
Embodiment 9 . The drug delivery system of any of embodiments 1-7, further
comprising a first inlet in the first chamber; a second inlet in the second chamber, a flow
control connected to the first inlet and the second inlet, a micropump connected to the flow
control, and an outlet connected to the micropump.
Embodiment 10. The drug delivery system of any of embodiments 1-9,
wherein the control module includes a graphical user interface that displays a temperature
received from the wireless drug delivery integrated circuit and is suitable for controlling the
wireless drug delivery integrated circuit;
and wherein the graphical user interface includes options of voltage applied, voltage
duration, initiation of the voltage applied, and stopping the voltage applied.
Embodiment 11 . A drug delivery method comprising:
providing a wireless drug delivery integrated circuit;
providing a control module suitable for controlling the wireless drug delivery
integrated circuit;
providing a first electrode and a second electrode, which are both attached to the
wireless drug delivery integrated circuit;
providing a first electroactive polymer;
providing a first pharmaceutical compound;
releasing the first pharmaceutical compound into a first solution by generating a first
voltage difference between the first electrode and the second electrode.
Embodiment 12. The method of embodiment 11, further comprising:
providing a third electrode and a fourth electrode and releasing a second pharmaceutical
compound.
Embodiment 13. The method of any of embodiments 11-12, further comprising:
providing a first chamber that contains the first solution, the first electrode, and the second
electrode;
providing a first inlet, a first micropump, and a first outlet,
controlling a release of the first pharmaceutical compound out of the first chamber using the
first inlet, the first micropump, and the first outlet.
Embodiment 14. The method of any of embodiments 11-13, wherein the first
electroactive polymer comprises oligoanilines linked to polycaprolactone (PCL, 2kDa) via
ester bonds.
Embodiment 15. The method of any of embodiments 11-14, wherein the first
electroactive polymer and the first pharmaceutical compound are layered in films on the
first electrode.
Embodiment 16. A drug delivery system comprising:
a drug delivery integrated circuit;
a first electrode and a second electrode, which are both attached to the drug delivery
integrated circuit;
a first electroactive polymer; and
a first pharmaceutical compound.
Embodiment 17. The drug delivery system of embodiment 16, wherein the first
electroactive polymer and the first pharmaceutical compound are layered as films on the
first electrode.
Embodiment 18. The drug delivery system of any of embodiments 16-17, wherein
the first electrode is comprised of a bioinert glassy carbon.
Embodiment 19. The drug delivery system of any of embodiments 16-18, wherein
the second electrode is comprised of steel, platinum, iridium oxide, gold, magnesium,
tungsten, silicon, orplatinum-iridium.
Embodiment 20. The drug delivery system of any of embodiments 16-19, further
comprising a third electrode and a fourth electrode in a second chamber with a second
pharmaceutical compound, and wherein the first electrode and the second electrode are
contained in a first chamber with the first pharmaceutical compound.
Embodiment 21. The drug delivery system of any of embodiments 16-20, further
comprising an inlet, an outlet, a chamber, and a micropump.
Embodiment 22. The drug delivery system of any of embodiments 16-21, further
comprising:
a first inlet, a first outlet, and a first micropump in the first chamber; and a second
inlet, a second outlet, and a second micropump in the second chamber.
Embodiment 23. The drug delivery system of any of embodiments 16-21, further
comprising a first inlet in the first chamber; a second inlet in the second chamber, a flow
control connected to the first inlet and the second inlet, a micropump connected to the flow
control, and an outlet connected to the micropump.
Embodiment 24. The drug delivery system of any of embodiments 16-23, wherein a
voltage is applied across the first electrode and the second electrode, and wherein the
voltage threshold is triggered by a measurement threshold.
Embodiment 25. The drug delivery system of embodiment 24, wherein the
measurement threshold is one or more of a timing sequence and a solution concentration.
Embodiment 26. The drug delivery system of embodiment 26, wherein the solution
concentration is one or more of a sugar concentration, salt concentration, and hormone
concentration.
A greater understanding of the present invention and of its many advantages may be
had from the following examples, given by way of illustration. The following examples are
illustrative of some of the methods, applications, embodiments and variants of the present
invention. They are, of course, not to be considered as limiting the invention. Numerous
changes and modifications can be made with respect to the invention.
EXAMPLE 1
A wireless drug delivery integrated circuit (WDDIC) as shown in Figure 7 was
fabricated. Another image of this WDDIC can be seen with its cover removed in Figure 8 .
The WDDIC included a low-power micro-controller (MCU), a 2.4-GHz wireless module, a
bias controller, a temperature sensor, and a boost converter. The WDDIC was designed to
be compact with the printed circuit board (PCB) having measurements close to that of a
standard credit card (85.7 x 54.0 mm, 3.375 x 2.125 in). The anode and cathode wires were
attached to a bias controller block and clipped to a platinum electrode (a platinum wire) and
a working electrode, which was made of bioinert glassy carbon and supported the polymer
films. The platinum electrode and the working electrode were immersed in PBS (4 mL) and
housed in a glass beaker with a fitted lid. The hardware was designed for low-power
consumption. The firmware of the MCU controlled the MCU itself, the wireless module on
the PCB, and the temperature sensor.
Active and sleep modes of the MCU were used to increase the length of the battery
life. Power was provided by a coin cell battery that would last for two or three months
under representative operating conditions. A Texas Instruments (TI) MSP430 MCU was
used, in part because it supports several layers of active and sleep modes. An external
32.768 kHz crystal oscillator was placed on the board for an auxiliary clock, which enabled
the use of deeper level of sleep modes by waking up the MCU using the auxiliary clock.
An Advanced and adaptive Network Technology (ANT) wireless module was mounted on
the board and connected to the MCU through a universal asynchronous receiver/transmitter
(UART) interface. The ANT is an ultra-low power wireless protocol that can send wireless
information from one device to another. The ANT supports many sensor network
topologies, such as peer- to-peer, star, and practical mesh. The 2.4-GHz ANT module can
use any R frequency from 2.4 to 2.524 GHz, other than 2.457 GHz (reserved for ANT+).
The MCU controls the ANT module during active or sleep modes. Effective use of the
sleep modes of the ANT module makes it possible to further reduce power consumption.
The bias controller block was designed and attached to the back of the main PCB. A
circuit diagram of the bias controller is shown in Figure 9 . One of the general-purpose
input/output (GPIO) pins was selected to control the applied voltage to the polymer films.
The bias controller block included an operational amplifier (OP-AMP) buffer circuit. A
LM386 OP-AMP was used as part of a buffer circuit. The input voltage of the buffer circuit
was 0.6 V. The desired voltage can be obtained by the divided ratio of two resistors R and
R 2 . One node of the resistor R is attached to the collector node of a PNP transistor. The
emitter node of the PNP transistors is attached to a 3.3-V output voltage of the boost
converter. The output of the buffer circuit was attached to the resistor(s) R P, which was
used for protection. The anode and cathode electrodes of the polymer films were connected
between the protection resistor R P and ground nodes. The collector nodes of NPN
transistors were attached to the base of PNP transistor, and the current of the base of the
PN transistors was controlled by the voltage level of one of the GPIO pins through the
resistor R B. For instance, if the level of the GPIO pin was high, there was 0.6 V difference
between the anode and cathode nodes of the polymer films. When the level of the GPIO pin
was low, there was approximately zero voltage across the anode and cathode nodes.
The microprocessor firmware was developed using mixed C and Assembly
languages. The structure of the firmware program was a finite state machine. First, the
controller device started operations with an initialization state. If the button was pressed in
a turned-off state or a new battery was inserted, the firmware began initialization of the
hardware. After the initialization state was finished, it went into a normal loop state. In the
normal loop state, the device executed essential operations such as controlling the wireless
module and temperature sensor and afterwards the controller device went into sleep mode.
The controller device was designed to wake up every two seconds and resume the normal
loop state when triggered by an internal wake up signal. For precise timing of drug release,
the start time of the active bias control signal lagged to the closest second to synchronize
with the MCU clock instead of immediate activation of the bias control signal. For safety,
if an emergency stop event occurred, the bias control signal was immediately rendered
inactive.
The wireless polymer conduction controller (control module) program was
developed using Visual C++. As described herein, the ANT wireless protocol was used for
communication. In the normal state of operation, the wireless polymer conduction
controller sent a broadcast information packet every two seconds as the WDDIC woke up
from the sleep mode. The information packet included temperature sensor data, the device
ID, and status information. The controller program received the packet data and then stored
and displayed the information.
A graphical user interface (GUI) control program on a laptop computer (control
module) managed communication with the WDDIC and received device information,
device status, and temperature data. The user interface of the wireless polymer conduction
controller program of this example is illustrated in Figure 10. A 'Release' button was
located on the right side. Above the "Release" button, there was a control duration drop
down menu, which can select pre-determined periods such as 10, 20, and 30 seconds, or a
user can manually type in the period. If the release button is clicked, the control program
sends an event to the WDDIC. If the received event is valid, the wireless controller sets the
bias control signal active for the given period of time. Afterwards, the controller sets the
bias control back to being inactive. Once the drug release process starts, the counter begins
counting backwards from the given time and the release button will not accept another click
event until the counter reaches zero so that accidently performing unwanted operations is
avoided. However, there is a stop button if the user wishes to cancel the ordered operation.
EXAMPLE 2
As shown in Figure 11, a non-wireless drug delivery integrated circuit (DDIC) was
constructed. A MSP430FG4618/F2013 experimenter board was used as the main
controller. The custom bias control circuits were placed in the lower right corner of the
experimenter board. Buttons and an LCD were used for selection of the pre-defined test
durations and voltages, and the start and stop of the test sequences. The bias controller
circuit used in this example, which did not include a LM386 buffer circuit, was a modified
version of the circuits shown in Figure 9 . The collector voltages of the PN and the PNP
transistors were provided by an external power supply. Anti-inflammatory DMP was used
as a clinically relevant model drug because it is straightforward to quantify its release using
UV spectroscopy. However, a wide variety of other biologically-active molecules can be
delivered using the methods described herein.
EXAMPLE 3
The DDIC of Example 2 was tested. The purpose of this experimentation was to test
the capability of the electroactive polymers to deliver DMP into a physiologically relevant
electrolyte solution of phosphate buffered saline (PBS).
Electroactive polymers were used to deliver dexamethasone phosphate (DMP). The
electroactive polymers consisted of blocks of electroactive oligoanilines linked to non-
electroactive polycaprolactone (PCL, 2kDa) via ester bonds and were prepared as described
in Hardy et al. ("Biodegradable ' electroactive polymers for electrochemically-triggered
drug delivery," 2014), which is incorporated by reference herein in its entirety. The
structure of this type of biodegradable electroactive polyester film is shown in Figure 6 . A
stock solution of the polymer and DMP (90 mg polymer, 10 mg DMP, 500 µΐ
hexafluoroisopropanol) was formed, and films of approximately 5 mg (as determined using
a high precision balance) were cast on bioinert glassy carbon working electrodes and dried
under high vacuum.
A constant electrical stimulation of 0.6V was applied for 30 seconds, followed by a
relaxation time of 9.5 minutes (i.e., for a total of 10 minutes). Then, the concentration of
DMP was determined using UV-visible spectroscopy. The films were stimulated again for
30 seconds and allowed to rest for another 9.5 minutes (i.e., for a total of 20 minutes), after
which the concentration of DMP was again determined. The films were then stimulated a
third time for 30 seconds and again allowed to rest for 9.5 minutes (i.e., for a total of 30
minutes), after which the concentration of DMP was finally measured. PBS is ideal for
measurement of DMP release by UV-visible spectroscopy, wherein the absorption of DMP
is measured at 242 nm (its absorption maximum). DMP release was quantified by UV
spectroscopy in accordance with the methodology of Gao et al. ("Action at a distance:
Functional drug delivery using electromagnetic-field-responsive polypyrrole nanowires,"
2014), which is incorporated by reference herein in its entirety. Measurements employed a
BioTek Epoch® plate reader (BioTek US, Winooski, VT) equipped with a Take3 Micro-
volume Plate and Gen5 v2.04 Software supplied with the plate reader.
Figure 12 shows the results of the DMP release experiments with electrical
stimulation, and without electrical stimulation (i.e., leaching of the drug from the polymer
matrix because the films swell when immersed in PBS). It was observed that more DMP
had leached out after an additional 20 minutes (30 minutes total time since immersion in
PBS). A second period of electrical stimulation enhanced the release of DMP relative to the
unstimulated films. The error bars represent standard deviations (n=5).
It should be understood that the examples and embodiments described herein are for
illustrative purposes only and that various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included within the spirit and purview of
this application.
All patents, patent applications, provisional applications, and publications referred to
or cited herein (including those in the "References" section) are incorporated by reference in
their entirety, including all figures and tables, to the extent they are not inconsistent with the
explicit teachings of this specification.
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CLAIMS
What is claimed is:
1 . A drug delivery system, comprising:
a control module;
a wireless drug delivery integrated circuit;
a first electrode and a second electrode, which are both attached to the wireless drug
delivery integrated circuit;
a first electroactive polymer; and
a first pharmaceutical compound.
2 . The drug delivery system according to claim 1, wherein the first electroactive
polymer and the first pharmaceutical compound are layered as films on the first electrode.
3 . The drug delivery system according to claim 1, wherein the wireless drug delivery
integrated circuit includes multiple antennas configured to supply energy to the wireless drug
delivery integrated circuit.
4 . The drug delivery system according to claim 1, wherein the first electrode
comprises a bioinert glassy carbon, and wherein the second electrode comprises platinum.
5 . The drug delivery system according to claim 1,
wherein the control module includes a graphical user interface that displays a temperature
received from the wireless drug delivery integrated circuit and is configured to control the
wireless drug delivery integrated circuit, and
wherein the graphical user interface includes options of voltage applied, voltage duration,
initiation of the voltage applied, and stopping the voltage applied.
6 . The drug delivery system according to claim 1, wherein the first electrode and the
second electrode are contained in a first chamber with the first pharmaceutical compound, and
wherein the drug delivery system further comprises a third electrode and a fourth
electrode in a second chamber with a second pharmaceutical compound.
7 . The drug delivery system according to claim 6, further comprising:
a first inlet, a first outlet, and a first micropump in the first chamber; and
a second inlet, a second outlet, and a second micropump in the second chamber.
8 . The drug delivery system according to claim 6, further comprising:
a first inlet in the first chamber;
a second inlet in the second chamber;
a flow control connected to the first inlet and the second inlet;
a micropump connected to the flow control; and
an outlet connected to the micropump.
9 . A drug delivery method, comprising:
providing a wireless drug delivery integrated circuit;
providing a control module suitable for controlling the wireless drug delivery integrated
circuit;
providing a first electrode and a second electrode, which are both attached to the wireless
drug delivery integrated circuit;
providing a first electroactive polymer;
providing a first pharmaceutical compound;
releasing the first pharmaceutical compound into a first solution by generating a first
voltage difference between the first electrode and the second electrode.
10. The method according to claim 9, further comprising:
providing a third electrode and a fourth electrode and releasing a second pharmaceutical
compound.
11. The method according to claim 9, further comprising:
providing a first chamber that contains the first solution, the first electrode, and the
second electrode;
providing a first inlet, a first micropump, and a first outlet; and
controlling a release of the first pharmaceutical compound out of the first chamber using
the first outlet, the first micropump, and the first outlet.
12. The method according to claim 9, wherein the first electroactive polymer and the
first pharmaceutical compound are layered in films on the first electrode.
13. The method according to claim 9, wherein the first electroactive polymer
comprises oligoanilines linked to polycaprolactone (PCL) via ester bonds.
14. A drug delivery system, comprising:
a drug delivery integrated circuit;
a first electrode and a second electrode, which are both attached to the drug delivery
integrated circuit;
a first electroactive polymer; and
a first pharmaceutical compound.
15. The drug delivery system according to claim 14, wherein the first electroactive
polymer and the first pharmaceutical compound are layered as films on the first electrode.
16. The drug delivery system according to claim 14, wherein a voltage is applied
across the first electrode and the second electrode,
wherein a voltage threshold is triggered by a measurement threshold, and
wherein the measurement threshold is at least one of a timing sequence and a solution
concentration, where the solution concentration is at least one of a sugar concentration, a salt
concentration, and a hormone concentration.
17. The drug delivery system according to claim 14, wherein the first electrode
comprises a bioinert glassy carbon, and
wherein the second electrode comprises at least one of steel, platinum, iridium oxide,
gold, magnesium, tungsten, silicon, and platinum-iridium.
18. The drug delivery system according to claim 14, wherein the first electrode and
the second electrode are contained in a first chamber with the first pharmaceutical compound,
and
wherein the drug delivery system further comprises a third electrode and a fourth
electrode in a second chamber with a second pharmaceutical compound.
19. The drug delivery system according to claim 18, further comprising:
a first inlet, a first outlet, and a first micropump in the first chamber; and
a second inlet, a second outlet, and a second micropump in the second chamber.
20. The drug delivery system according to claim 18, further comprising:
a first inlet in the first chamber;
a second inlet in the second chamber;
a flow control connected to the first inlet and the second inlet;
a micropump connected to the flow control;
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